Aquestive Therapeutics (NASDAQ:AQST) Announces Quarterly Earnings Results

Key Points

• Aquestive Therapeutics reported a quarterly EPS of ($0.14), exceeding analysts' expectations of ($0.18) by $0.04.
• Aquestive Therapeutics' stock has a current trading price of $3.86 and a market capitalization of $383.41 million, reflecting a 1.0% decrease on the day.
• Equities analysts have rated the stock with an average rating of "Buy" and an average price target of $10.14, indicating positive investor sentiment.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04, Zacks reports. Aquestive Therapeutics updated its FY 2025 guidance to EPS.

Aquestive Therapeutics Stock Down 1.0%

Shares of AQST stock traded down $0.04 on Monday, reaching $3.86. The company's stock had a trading volume of 875,194 shares, compared to its average volume of 1,487,800. Aquestive Therapeutics has a 12-month low of $2.12 and a 12-month high of $5.80. The company has a market capitalization of $383.41 million, a P/E ratio of -6.54 and a beta of 1.99. The stock's 50 day simple moving average is $3.70 and its 200-day simple moving average is $3.12.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, June 17th. Oppenheimer assumed coverage on Aquestive Therapeutics in a report on Monday, June 2nd. They issued an "outperform" rating and a $7.00 price target for the company. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Aquestive Therapeutics has an average rating of "Buy" and an average price target of $10.14.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Creative Planning raised its position in Aquestive Therapeutics by 15.3% during the second quarter. Creative Planning now owns 98,751 shares of the company's stock valued at $327,000 after purchasing an additional 13,130 shares in the last quarter. Geode Capital Management LLC raised its position in Aquestive Therapeutics by 16.2% during the second quarter. Geode Capital Management LLC now owns 1,977,001 shares of the company's stock valued at $6,545,000 after purchasing an additional 276,295 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in Aquestive Therapeutics by 12.2% during the first quarter. AQR Capital Management LLC now owns 129,019 shares of the company's stock valued at $374,000 after purchasing an additional 14,025 shares in the last quarter. Hedge funds and other institutional investors own 32.45% of the company's stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.